Breast Cancer Clinical Trial
Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer
Summary
This phase II trial studies the side effects of nab-paclitaxel in treating older patients with breast cancer that has spread from where it started to nearby tissue or lymph nodes (locally advanced) or to other places in the body (metastatic). Drugs used in chemotherapy, such as nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Full Description
PRIMARY OBJECTIVE:
I. To evaluate the tolerability (grade 2-5 toxicity, neuropathy grade 2 or higher, need for dose reductions, or delays) of weekly nab-paclitaxel in older adults with locally advanced or metastatic breast cancer.
SECONDARY OBJECTIVES:
I. To evaluate the efficacy (response and time to progression) of weekly nab-paclitaxel in older adults with locally advanced or metastatic breast cancer using a stratification factor based on patient age (at least 5 patients age 75 years or older and no more than 15 patients age 65-70 years).
II. To explore predictors of the need for dose reduction, dose delays, or grade 2-5 toxicity and neuropathy grade 2 or higher based on a cancer-specific geriatric assessment.
OUTLINE:
Patients receive nab-paclitaxel intravenously (IV) over 30 minutes on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up periodically.
Eligibility Criteria
Inclusion Criteria:
Locally advanced or metastatic breast cancer
Any estrogen receptor (ER), progesterone receptor (PR), or human epidermal growth factor receptor 2 (Her2neu) status as long as the patient will receive nab-paclitaxel alone
First or second line chemotherapy treatment for metastatic disease
Karnofsky performance status (KPS) >= 70%
Resolution of grade >= 2 toxicity from prior therapy (other than alopecia)
Peripheral neuropathy =< grade 1
Absolute neutrophil count >= 1,500/mm^3
Platelets >= 100,000 cells/mm^3
Hemoglobin (Hb) >= 9.0 g/dl
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional upper limit of normal
Alkaline phosphatase =< 2.5 x upper limit of normal unless bone metastasis are present in the absence of liver metastases
Bilirubin =< 1.5 mg/dl
Creatinine clearance (calculated or 24 hour) >= 30 ml/min
Ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria:
Patients may not be receiving any other investigational agents
Untreated central nervous system (CNS) metastases or symptomatic CNS metastases requiring escalating doses of corticosteroids
Known history of allergic reactions to paclitaxel
Presence of any serious or uncontrolled infection
Receipt of a taxane for adjuvant therapy or metastatic disease in the last 12 months
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 4 Locations for this study
Duarte California, 91010, United States
Lancaster California, 93534, United States
South Pasadena California, 91030, United States
Columbus Ohio, 43210, United States
How clear is this clinincal trial information?